Bay Street News, March, 2024

MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis […]

PASCAGOULA, Miss., March 04, 2024 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division announced today the successful completion of […]

OMAHA, Neb., March 04, 2024 (GLOBE NEWSWIRE) — Greystone Housing Impact Investors LP, a Delaware limited partnership, (NYSE: GHI) (the […]

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company […]

BURLINGTON, Mass., March 04, 2024 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced that […]

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation […]

LONDON, March 04, 2024 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company”, “Global Ship Lease” or “GSL”), […]

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages 2-5 with […]

HOLLYWOOD, Fla., March 04, 2024 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of […]

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage […]